Systemic sarcoidosis with bone marrow involvement responding to therapy with adalimumab: a case report
Author:
Open Access
- 1 January 2009
- journal article
- Published by Springer Nature in Journal of Medical Case Reports
- Vol. 3 (1) , 8573
Abstract
Sarcoidosis is an inflammatory disorder characterized by the presence of non-caseating granulomas in affected organs. The presence of CD4-positive T lymphocytes and macrophages in affected organs suggests an ongoing immune response. Systemic corticosteroids remain the mainstay of treatment, but therapy is often limited by adverse effects. This is the first report of the use of adalimumab (HUMIRA®, Abbott Laboratories, North Chicago, IL, USA), an anti-tumor necrosis factor monoclonal antibody, in a patient with systemic sarcoidosis with bone marrow involvement.Keywords
This publication has 17 references indexed in Scilit:
- Treatment of therapy-resistant sarcoidosis with adalimumabClinical Rheumatology, 2005
- Treatment of Sarcoidosis With InfliximabChest, 2005
- Tumour necrosis factor α inhibitor treatment for sarcoidosis refractory to conventional treatments: a report of five patientsAnnals of the Rheumatic Diseases, 2004
- Successful tumor necrosis factor α blockade treatment in therapy‐resistant sarcoidosisArthritis & Rheumatism, 2003
- Refractory Sarcoidosis Responding to Infliximab *Chest, 2003
- Progressive cutaneous sarcoidosis responding to anti-tumor necrosis factor-? therapyJournal of the American Academy of Dermatology, 2003
- Clinical Characteristics of Patients in a Case Control Study of SarcoidosisAmerican Journal of Respiratory and Critical Care Medicine, 2001
- Treatment of Complicated Sarcoidosis with Infliximab Anti–Tumor Necrosis Factor-α TherapyAnnals of Internal Medicine, 2001
- SarcoidosisNew England Journal of Medicine, 1997
- Differential diagnoses of bone marrow granuloma.1996